Phosphoproteomic	O
analysis	O
of	O
anaplastic	B-GP
lymphoma	I-GP
kinase	I-GP
(	O
ALK	B-GP
)	O
downstream	O
signaling	O
pathways	O
identifies	O
signal	B-GP
transducer	I-GP
and	I-GP
activator	I-GP
of	I-GP
transcription	I-GP
3	I-GP
as	O
a	O
functional	O
target	O
of	O
activated	O
ALK	B-GP
in	O
neuroblastoma	B-DS
cells	O

Activation	O
of	O
the	O
anaplastic	B-GP
lymphoma	I-GP
kinase	I-GP
(	O
ALK	B-GP
)	O
receptor	B-GP
tyrosine	I-GP
kinase	I-GP
is	O
a	O
key	O
oncogenic	O
mechanism	O
in	O
a	O
growing	O
number	O
of	O
tumor	B-DS
types	O
.	O

In	O
the	O
majority	O
of	O
cases	O
,	O
ALK	B-GP
is	O
activated	O
by	O
fusion	O
with	O
a	O
dimerizing	O
partner	O
protein	O
as	O
a	O
result	O
of	O
chromosomal	O
translocation	O
events	O
,	O
most	O
studied	O
in	O
the	O
case	O
of	O
the	O
nucleophosmin	B-GP
–	O
ALK	B-GP
and	O
echinoderm	B-GP
microtubule	I-GP
-	I-GP
associated	I-GP
protein	I-GP
-	I-GP
like	I-GP
4	I-GP
–	O
ALK	B-GP
oncoproteins	I-GP
.	O

It	O
is	O
now	O
also	O
appreciated	O
that	O
the	O
full	O
-	O
length	O
ALK	B-GP
receptor	I-GP
can	O
be	O
activated	O
by	O
point	O
mutations	O
and	O
by	O
deletions	O
within	O
the	O
extracellular	O
domain	O
,	O
such	O
as	O
those	O
observed	O
in	O
neuroblastoma	B-DS
.	O

Several	O
studies	O
have	O
employed	O
phosphoproteomics	O
approaches	O
to	O
find	O
substrates	O
of	O
ALK	B-GP
fusion	O
proteins	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
MS	O
-	O
based	O
phosphotyrosine	O
profiling	O
to	O
characterize	O
phosphotyrosine	O
signaling	O
events	O
associated	O
with	O
the	O
full	O
-	O
length	O
ALK	B-GP
receptor	I-GP
.	O

A	O
number	O
of	O
previously	O
identified	O
and	O
novel	O
targets	O
were	O
identified	O
.	O

One	O
of	O
these	O
,	O
signal	B-GP
transducer	I-GP
and	I-GP
activator	I-GP
of	I-GP
transcription	I-GP
3	I-GP
(	O
STAT3	B-GP
),	O
has	O
previously	O
been	O
observed	O
to	O
be	O
activated	O
in	O
response	O
to	O
oncogenic	O
ALK	B-GP
signaling	O
,	O
but	O
the	O
significance	O
of	O
this	O
in	O
signaling	O
from	O
the	O
full	O
-	O
length	O
ALK	B-GP
receptor	I-GP
has	O
not	O
been	O
explored	O
further	O
.	O

We	O
show	O
here	O
that	O
activated	O
ALK	B-GP
robustly	O
activates	O
STAT3	B-GP
on	O
Tyr705	O
in	O
a	O
number	O
of	O
independent	O
neuroblastoma	B-DS
cell	O
lines	O
.	O

Furthermore	O
,	O
knockdown	O
of	O
STAT3	B-GP
by	O
RNA	O
interference	O
resulted	O
in	O
a	O
reduction	O
in	O
myelocytomatosis	O
neuroblastom	O
(	O
MYCN	B-GP
)	O
protein	O
levels	O
downstream	O
of	O
ALK	B-GP
signaling	O
.	O

These	O
observations	O
,	O
together	O
with	O
a	O
decreased	O
level	O
of	O
MYCN	B-GP
and	O
inhibition	O
of	O
neuroblastoma	B-DS
cell	O
growth	O
in	O
the	O
presence	O
of	O
STAT3	B-GP
inhibitors	O
,	O
suggest	O
that	O
activation	O
of	O
STAT3	B-GP
is	O
important	O
for	O
ALK	B-GP
signaling	O
activity	O
in	O
neuroblastoma	B-DS
.	O

Introduction	O

Many	O
of	O
the	O
tyrosine	B-GP
kinases	I-GP
in	O
the	O
human	B-OG
kinome	O
are	O
implicated	O
in	O
human	B-OG
cancers	B-DS
1	O
,	O
and	O
provide	O
important	O
targets	O
for	O
cancer	B-DS
treatment	O
,	O
as	O
well	O
as	O
biomarkers	O
for	O
patient	O
stratification	O
.	O

Recently	O
,	O
tyrosine	B-GP
kinase	I-GP
inhibitors	O
targeting	O
anaplastic	B-GP
lymphoma	I-GP
kinase	I-GP
(	O
ALK	B-GP
)	O
have	O
been	O
approved	O
for	O
the	O
treatment	O
of	O
ALK	B-GP
-	O
positive	O
non	B-DS
-	I-DS
small	I-DS
-	I-DS
cell	I-DS
-	I-DS
lung	I-DS
-	I-DS
cancer	I-DS
(	O
NSCLC	B-DS
)	O
2	O
.	O

In	O
NSCLC	B-DS
,	O
ALK	B-GP
activation	O
occurs	O
via	O
chromosomal	O
translocation	O
,	O
leading	O
to	O
activation	O
of	O
the	O
kinase	B-GP
domain	O
.	O

However	O
,	O
ALK	B-GP
is	O
also	O
known	O
to	O
be	O
mutated	O
in	O
the	O
context	O
of	O
the	O
full	O
-	O
length	O
receptor	B-GP
tyrosine	I-GP
kinase	I-GP
(	O
RTK	B-GP
),	O
this	O
being	O
most	O
clearly	O
understood	O
in	O
neuroblastoma	B-DS
.	O

Neuroblastoma	B-DS
is	O
a	O
childhood	B-DS
cancer	I-DS
that	O
stems	O
from	O
the	O
sympathetic	O
nervous	O
system	O
3	O
,	O
most	O
commonly	O
originating	O
in	O
the	O
adrenal	O
glands	O
,	O
but	O
also	O
developing	O
at	O
additional	O
sites	O
in	O
the	O
neck	O
,	O
chest	O
,	O
and	O
abdomen	O
.	O

It	O
is	O
considered	O
to	O
be	O
a	O
disease	O
of	O
developing	O
tissue	O
,	O
as	O
it	O
originates	O
from	O
precursor	O
cells	O
of	O
neural	O
crest	O
tissue	O
that	O
are	O
active	O
during	O
embryonic	O
development	O
4	O
.	O

ALK	B-GP
gain	O
-	O
of	O
-	O
function	O
mutations	O
have	O
been	O
described	O
in	O
both	O
familial	O
5	O
–	O
6	O
and	O
sporadic	O
6	O
–	O
10	O
neuroblastoma	B-DS
.	O

Although	O
there	O
is	O
currently	O
no	O
clinically	O
approved	O
specific	O
treatment	O
for	O
ALK	B-GP
mutations	O
in	O
neuroblastoma	B-DS
,	O
ongoing	O
clinical	O
trials	O
are	O
being	O
conducted	O
to	O
determine	O
the	O
potential	O
usefulness	O
of	O
ALK	B-GP
-	O
targeted	O
therapies	O
for	O
use	O
in	O
future	O
treatment	O
approaches	O
11	O
.	O

Today	O
,	O
crizotinib	O
(	O
PF	O
-	O
02341066	O
)	O
is	O
in	O
use	O
as	O
a	O
Food	O
and	O
Drug	O
Administration	O
-	O
approved	O
drug	O
for	O
the	O
treatment	O
of	O
ALK	B-GP
-	O
positive	O
NSCLC	B-DS
12	O
.	O

Clinical	O
studies	O
today	O
suggest	O
that	O
anti	O
-	O
ALK	B-GP
inhibitor	O
therapy	O
offers	O
promise	O
in	O
the	O
treatment	O
of	O
ALK	B-GP
-	O
mediated	O
tumors	B-DS
2	O
,	O
11	O
.	O

One	O
consistent	O
problem	O
with	O
kinase	B-GP
inhibitors	O
and	O
their	O
use	O
in	O
a	O
more	O
personalized	O
therapy	O
approach	O
is	O
the	O
drug	O
-	O
resistant	O
mutations	O
that	O
arise	O
in	O
response	O
to	O
treatment	O
,	O
most	O
commonly	O
within	O
the	O
ATP	O
-	O
binding	O
site	O
of	O
the	O
kinase	B-GP
in	O
question	O
.	O

Originally	O
described	O
in	O
the	O
epidermal	B-GP
growth	I-GP
factor	I-GP
receptor	I-GP
and	O
breakpoint	O
cluster	O
region	O
–	O
c	O
-	O
abl	B-GP
kinase	I-GP
domains	O
14	O
–	O
18	O
,	O
this	O
has	O
now	O
also	O
been	O
described	O
for	O
echinoderm	O
microtubule	O
-	O
associated	O
protein	O
-	O
like	O
4	O
(	O
EML4	B-GP
)–	O
ALK	B-GP
by	O
Choi	O
et	O
al	O
.,	O
and	O
others	O
who	O
have	O
described	O
the	O
appearance	O
of	O
such	O
mutations	O
in	O
the	O
fusion	O
EML4	B-GP
–	O
ALK	B-GP
protein	O
that	O
confers	O
resistance	O
to	O
crizotinib	O
19	O
–	O
22	O
.	O

Phase	O
I	O
/	O
II	O
studies	O
of	O
crizotinib	O
in	O
children	O
with	O
relapsed	O
/	O
refractory	O
tumors	B-DS
involving	O
ALK	B-GP
,	O
including	O
neuroblastoma	B-DS
patients	O
,	O
have	O
been	O
initiated	O
(	O
ClinicalTrials	O
.	O
gov	O
,	O
NCT01182896	O
)	O
23	O
.	O

Given	O
the	O
increasing	O
clinical	O
importance	O
of	O
ALK	B-GP
activity	O
,	O
we	O
chose	O
to	O
characterize	O
ALK	B-GP
-	O
mediated	O
tyrosine	B-GP
kinase	I-GP
signaling	O
networks	O
by	O
MS	O
-	O
based	O
phosphoproteomics	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
conducted	O
a	O
comprehensive	O
profiling	O
of	O
endogenous	O
proteins	O
that	O
are	O
tyrosine	O
-	O
phosphorylated	O
upon	O
expression	O
and	O
activation	O
of	O
wild	O
-	O
type	O
ALK	B-GP
in	O
PC12	O
cells	O
,	O
a	O
cell	O
line	O
originally	O
from	O
the	O
rat	B-OG
neural	O
crest	O
.	O

This	O
list	O
,	O
which	O
reflects	O
both	O
direct	O
and	O
indirect	O
tyrosine	O
phosphorylation	O
targets	O
as	O
a	O
result	O
of	O
ALK	B-GP
activity	O
within	O
the	O
cell	O
,	O
verifies	O
several	O
recently	O
published	O
results	O
such	O
as	O
fibroblast	B-GP
growth	I-GP
factor	I-GP
receptor	I-GP
substrate	I-GP
2	I-GP
(	O
FRS2	B-GP
)	O
23	O
.	O

One	O
of	O
the	O
proteins	O
that	O
was	O
most	O
significantly	O
tyrosine	O
-	O
phosphorylated	O
in	O
response	O
to	O
ALK	B-GP
activation	O
in	O
our	O
analysis	O
was	O
signal	B-GP
transducer	I-GP
and	I-GP
activator	I-GP
of	I-GP
transcription	I-GP
3	I-GP
(	O
STAT3	B-GP
),	O
which	O
has	O
previously	O
been	O
reported	O
to	O
be	O
phosphorylated	O
by	O
both	O
the	O
full	O
-	O
length	O
ALK	B-GP
and	O
ALK	B-GP
fusion	O
proteins	O
24	O
–	O
27	O
.	O

Here	O
,	O
we	O
investigated	O
this	O
further	O
,	O
and	O
clarified	O
the	O
importance	O
of	O
STAT3	B-GP
as	O
a	O
mediator	O
in	O
the	O
initiation	O
of	O
transcription	O
of	O
MYCN	B-GP
.	O

Results	O

Phosphotyrosine	O
profiling	O
of	O
PC12	O
cells	O
expressing	O
ALK	B-GP

To	O
identify	O
sites	O
with	O
altered	O
phosphorylation	O
associated	O
with	O
ALK	B-GP
RTK	B-GP
activity	O
,	O
we	O
utilized	O
an	O
immunoaffinity	O
-	O
coupled	O
LC	O
-	O
MS	O
/	O
MS	O
approach	O
on	O
PC12	O
Tet	O
-	O
on	O
-	O
inducible	O
cell	O
lines	O
.	O

After	O
induction	O
,	O
ALK	B-GP
was	O
activated	O
by	O
addition	O
of	O
agonist	O
mAbs	O
that	O
have	O
previously	O
been	O
reported	O
to	O
initiate	O
ALK	B-GP
signaling	O
pathways	O
10	O
–	O
28	O
.	O

Comparison	O
with	O
controls	O
expressing	O
unstimulated	O
ALK	B-GP
allowed	O
quantification	O
of	O
336	O
phosphorylation	O
sites	O
(	O
207	O
phosphotyrosine	O
,	O
78	O
phosphoserine	O
,	O
and	O
51	O
phosphothreonine	O
)	O
derived	O
from	O
189	O
different	O
proteins	O
(	O
Table	O
S1	O
).	O

Label	O
-	O
free	O
quantification	O
of	O
ALK	B-GP
-	O
activated	O
versus	O
control	O
cells	O
revealed	O
101	O
phosphorylation	O
sites	O
(	O
73	O
phosphotyrosine	O
,	O
13	O
phosphoserine	O
,	O
and	O
15	O
phosphothreonine	O
)	O
in	O
72	O
proteins	O
,	O
with	O
a	O
more	O
than	O
five	O
-	O
fold	O
increase	O
in	O
corresponding	O
phosphopeptide	O
intensities	O
.	O

In	O
contrast	O
,	O
only	O
19	O
phosphorylation	O
sites	O
in	O
12	O
proteins	O
were	O
found	O
with	O
decreased	O
phosphorylation	O
following	O
ALK	B-GP
induction	O
.	O

Within	O
the	O
list	O
of	O
mapped	O
phosphorylation	O
sites	O
,	O
we	O
identified	O
11	O
phosphotyrosine	O
sites	O
that	O
belong	O
to	O
ALK	B-GP
(	O
Fig	O
.	O
1A	O
).	O

As	O
expected	O
,	O
all	O
of	O
them	O
showed	O
a	O
significant	O
increase	O
in	O
the	O
level	O
of	O
phosphorylation	O
on	O
activation	O
of	O
ALK	B-GP
with	O
mAb	O
as	O
compared	O
with	O
control	O
cells	O
(	O
Table	O
S1	O
).	O

The	O
identified	O
tyrosine	O
phosphorylation	O
sites	O
in	O
full	O
-	O
length	O
ALK	B-GP
overlap	O
with	O
the	O
predicted	O
ones	O
(	O
PhosphoMotif	O
,	O
Human	B-OG
Protein	O
Reference	O
Database	O
,	O
http	O
://	O
www	O
.	O
hprd	O
.	O
org	O
/	O
PhosphoMotif_finder	O
),	O
and	O
cover	O
,	O
with	O
only	O
one	O
exception	O
,	O
the	O
entire	O
set	O
of	O
mapped	O
phosphotyrosine	O
sites	O
from	O
earlier	O
investigations	O
of	O
EML4	B-GP
–	O
ALK	B-GP
and	O
nucleophosmin	B-GP
(	O
NPM	B-GP
)–	O
ALK	B-GP
29	O
,	O
30	O
.	O

(	O
A	O
)	O
Tyrosine	O
residues	O
phosphorylated	O
in	O
the	O
kinase	B-GP
domain	O
of	O
ALK	B-GP
.	O

The	O
intracellular	O
domain	O
of	O
ALK	B-GP
containing	O
the	O
protein	O
kinase	B-GP
domain	O
(	O
PKD	O
)	O
(	O
red	O
)	O
and	O
potential	O
autophosphorylation	O
sites	O
were	O
searched	O
with	O
phosphomotif	O
(	O
http	O
://	O
www	O
.	O
hprd	O
.	O
org	O
/	O
PhosphoMotif_finder	O
)	O
as	O
indicated	O
.	O

Presented	O
and	O
compared	O
side	O
-	O
by	O
-	O
side	O
with	O
our	O
phosphotyrosine	O
mapping	O
of	O
activated	O
full	O
-	O
length	O
ALK	B-GP
are	O
the	O
global	O
surveys	O
of	O
phosphotyrosine	O
peptides	O
identified	O
in	O
EML4	B-GP
–	O
ALK	B-GP
and	O
NPM	B-GP
–	O
ALK	B-GP
29	O
,	O
30	O
.	O

The	O
critical	O
tyrosines	O
in	O
the	O
activation	O
loop	O
of	O
the	O
kinase	B-GP
domain	O
of	O
ALK	B-GP
are	O
boxed	O
45	O
.	O

(	O
B	O
)	O
Protein	O
–	O
protein	O
interactions	O
of	O
human	B-OG
orthologs	O
of	O
the	O
phosphoproteins	B-GP
identified	O
in	O
ALK	B-GP
-	O
expressing	O
PC12	O
cells	O
.	O

In	O
the	O
network	O
,	O
proteins	O
with	O
upregulated	O
phosphorylation	O
sites	O
in	O
activated	O
ALK	B-GP
-	O
expressing	O
PC12	O
cells	O
as	O
compared	O
with	O
control	O
cells	O
are	O
in	O
red	O
,	O
and	O
proteins	O
with	O
downregulated	O
phosphorylation	O
sites	O
are	O
in	O
green	O
.	O

Blue	O
edges	O
indicate	O
protein	O
–	O
protein	O
interactions	O
,	O
and	O
orange	O
edges	O
indicate	O
kinase	B-GP
–	O
substrate	O
relationships	O
.	O

Only	O
the	O
network	O
including	O
ALK	B-GP
is	O
shown	O
.	O

The	O
pale	O
blue	O
balls	O
indicate	O
(	O
human	B-OG
orthologs	O
of	O
)	O
PC12	O
proteins	O
with	O
identified	O
/	O
mapped	O
phosphotyrosines	O
that	O
were	O
not	O
found	O
to	O
be	O
significantly	O
regulated	O
.	O

To	O
highlight	O
potential	O
direct	O
downstream	O
substrates	O
of	O
full	O
-	O
length	O
ALK	B-GP
,	O
a	O
network	O
analysis	O
using	O
known	O
protein	O
–	O
protein	O
interactions	O
and	O
experimentally	O
verified	O
kinase	B-GP
–	O
substrate	O
relationships	O
of	O
the	O
human	B-OG
orthologs	O
of	O
the	O
identified	O
phosphoproteins	B-GP
was	O
performed	O
(	O
Fig	O
.	O
1B	O
).	O

The	O
network	O
model	O
illustrated	O
two	O
of	O
the	O
identified	O
phosphoproteins	B-GP
with	O
increased	O
phosphorylation	O
as	O
potential	O
direct	O
targets	O
of	O
ALK	B-GP
following	O
ALK	B-GP
induction	O
,	O
namely	O
PTPN11	B-GP
(	O
SHP	B-GP
-	I-GP
2	I-GP
)	O
and	O
STAT3	B-GP
.	O

Neither	O
of	O
these	O
has	O
previously	O
been	O
shown	O
to	O
interact	O
with	O
full	O
-	O
length	O
ALK	B-GP
.	O

In	O
agreement	O
with	O
a	O
role	O
for	O
these	O
proteins	O
downstream	O
of	O
ALK	B-GP
,	O
we	O
detected	O
approximately	O
10	O
-	O
fold	O
higher	O
phosphorylation	O
at	O
Tyr546	O
and	O
Tyr584	O
in	O
SHP	B-GP
-	I-GP
2	I-GP
as	O
well	O
as	O
Tyr705	O
in	O
STAT3	B-GP
under	O
ALK	B-GP
-	O
activating	O
conditions	O
in	O
our	O
model	O
.	O

Furthermore	O
,	O
identified	O
downstream	O
targets	O
of	O
ALK	B-GP
detected	O
in	O
this	O
phosphoprofiling	O
,	O
such	O
as	O
mitogen	B-GP
-	I-GP
activated	I-GP
protein	I-GP
kinase	I-GP
(	B-GP
MAPK	I-GP
)	I-GP
1	I-GP
,	O
MAPK3	B-GP
[	O
extracellular	B-GP
signal	I-GP
-	I-GP
related	I-GP
kinase	I-GP
(	I-GP
ERK	I-GP
)	I-GP
2	I-GP
/	I-GP
1	I-GP
],	O
glycogen	B-GP
synthase	I-GP
kinase	I-GP
-	I-GP
3α	I-GP
,	O
STAT3	B-GP
,	O
FAK	B-GP
,	O
and	O
CRKL	B-GP
(	O
Table	O
S1	O
),	O
showed	O
decreased	O
phosphorylation	O
upon	O
abrogation	O
of	O
ALK	B-GP
activity	O
in	O
several	O
neuroblastoma	B-DS
cell	O
lines	O
(	O
Fig	O
.	O
S1	O
).	O

ALK	B-GP
activates	O
STAT3	B-GP
in	O
PC12	O
cells	O

We	O
subsequently	O
decided	O
to	O
focus	O
in	O
more	O
detail	O
on	O
one	O
of	O
the	O
most	O
prominent	O
hits	O
from	O
the	O
phosphotyrosine	O
proteomics	O
screen	O
,	O
namely	O
STAT3	B-GP
.	O

As	O
observed	O
in	O
the	O
screen	O
,	O
activation	O
of	O
ALK	B-GP
resulted	O
in	O
clear	O
phosphorylation	O
of	O
STAT3	B-GP
at	O
Tyr705	O
.	O

PC12	O
cells	O
expressing	O
either	O
doxycycline	O
-	O
inducible	O
wild	O
-	O
type	O
ALK	B-GP
or	O
the	O
ALKF1174S	O
mutant	O
were	O
employed	O
to	O
examine	O
STAT3	B-GP
activation	O
.	O

As	O
ALK	B-GP
is	O
still	O
regarded	O
as	O
an	O
orphan	O
receptor	O
,	O
the	O
ALK	B-GP
receptor	I-GP
was	O
stimulated	O
with	O
an	O
agonist	O
mAb	O
that	O
has	O
been	O
previously	O
reported	O
to	O
bind	O
and	O
activate	O
ALK	B-GP
in	O
a	O
cell	O
culture	O
model	O
28	O
,	O
32	O
.	O

Interestingly	O
,	O
whereas	O
long	O
-	O
term	O
stimulation	O
of	O
the	O
wild	O
-	O
type	O
ALK	B-GP
receptor	I-GP
did	O
lead	O
to	O
visible	O
tyrosine	O
phosphorylation	O
of	O
STAT3	B-GP
,	O
this	O
was	O
not	O
prominently	O
observed	O
after	O
30	O
min	O
of	O
stimulation	O
,	O
a	O
time	O
point	O
when	O
ALK	B-GP
and	O
ERK1	B-GP
/	O
2	O
were	O
highly	O
phosphorylated	O
(	O
Fig	O
.	O
2A	O
,	O
compare	O
lanes	O
3	O
and	O
4	O
).	O

This	O
is	O
in	O
contrast	O
to	O
the	O
robust	O
activation	O
of	O
STAT3	B-GP
observed	O
upon	O
induction	O
of	O
expression	O
of	O
the	O
ALKF1174S	O
mutant	O
(	O
Fig	O
.	O
2A	O
,	O
compare	O
lanes	O
3	O
and	O
7	O
).	O

In	O
both	O
cases	O
,	O
tyrosine	O
phosphorylation	O
of	O
STAT3	B-GP
was	O
abrogated	O
by	O
the	O
addition	O
of	O
the	O
ALK	B-GP
inhibitor	O
crizotinib	O
(	O
Fig	O
.	O
2A	O
,	O
compare	O
lanes	O
4	O
and	O
7	O
with	O
lanes	O
5	O
and	O
8	O
).	O

STAT3	B-GP
phosphorylation	O
and	O
interaction	O
with	O
ALK	B-GP
on	O
ALK	B-GP
activation	O
.	O

(	O
A	O
)	O
Tet	O
-	O
on	O
-	O
inducible	O
PC12	O
cell	O
clones	O
expressing	O
either	O
wild	O
-	O
type	O
ALK	B-GP
or	O
the	O
ALKF1174S	O
mutant	O
receptor	O
were	O
employed	O
.	O

Protein	O
expression	O
was	O
induced	O
with	O
1	O
μg	O
·	O
mL	O
−	O
1	O
doxycycline	O
,	O
and	O
cells	O
were	O
serum	O
-	O
starved	O
for	O
24	O
h	O
prior	O
to	O
stimulation	O
with	O
1	O
μg	O
·	O
mL	O
−	O
1	O
ALK	B-GP
-	O
activating	O
mAb	O
(	O
mAb31	O
)	O
for	O
30	O
min	O
or	O
24	O
h	O
.	O

Whole	O
cell	O
lysates	O
were	O
analyzed	O
by	O
SDS	O
/	O
PAGE	O
,	O
and	O
this	O
was	O
followed	O
by	O
immunoblotting	O
with	O
antibodies	O
against	O
p	O
-	O
ALKY1278	O
,	O
ALK	B-GP
,	O
p	O
-	O
STAT3Y705	O
,	O
and	O
p	O
-	O
ERK	B-GP
.	O

Pan	O
-	O
ERK	B-GP
and	O
pan	O
-	O
STAT3	B-GP
antibodies	O
were	O
employed	O
as	O
loading	O
controls	O
.	O

(	O
B	O
,	O
C	O
)	O
PC12	O
cells	O
were	O
transfected	O
with	O
either	O
wild	O
-	O
type	O
ALK	B-GP
or	O
the	O
ALKF1174S	O
mutant	O
together	O
with	O
FLAG	B-GP
-	O
tagged	O
STAT3	B-GP
prior	O
to	O
stimulation	O
with	O
1	O
μg	O
·	O
mL	O
−	O
1	O
ALK	B-GP
-	O
activating	O
mAb	O
(	O
mAb46	O
)	O
for	O
24	O
h	O
,	O
in	O
the	O
presence	O
or	O
absence	O
of	O
250	O
nm	O
crizotinib	O
,	O
as	O
indicated	O
.	O

Lysates	O
were	O
immunoprecipitated	O
(	O
IP	O
)	O
with	O
either	O
antibody	O
against	O
FLAG	B-GP
(	O
M2	O
)	O
(	O
B	O
)	O
or	O
with	O
antibody	O
against	O
ALK	B-GP
(	O
mAb31	O
)	O
(	O
C	O
),	O
and	O
this	O
was	O
followed	O
by	O
immunoblotting	O
for	O
ALK	B-GP
,	O
FLAG	B-GP
,	O
and	O
STAT3	B-GP
,	O
as	O
indicated	O
.	O

WCL	O
,	O
whole	O
cell	O
lysate	O
.	O

To	O
investigate	O
the	O
activation	O
process	O
further	O
,	O
we	O
examined	O
whether	O
an	O
interaction	O
between	O
ALK	B-GP
and	O
STAT3	B-GP
could	O
occur	O
.	O

We	O
were	O
unable	O
to	O
observe	O
an	O
interaction	O
between	O
doxycycline	O
-	O
induced	O
ALK	B-GP
and	O
endogenous	O
STAT3	B-GP
in	O
PC12	O
cells	O
(	O
data	O
not	O
shown	O
).	O

However	O
,	O
an	O
interaction	O
between	O
STAT3	B-GP
and	O
ALK	B-GP
was	O
observed	O
on	O
immmunoprecipitation	O
of	O
tagged	O
STAT3	B-GP
,	O
when	O
wild	O
-	O
type	O
ALK	B-GP
was	O
transiently	O
cotransfected	O
with	O
FLAG	B-GP
-	O
tagged	O
STAT3	B-GP
(	O
Fig	O
.	O
2B	O
).	O

Upon	O
stimulation	O
of	O
ALK	B-GP
,	O
increased	O
interaction	O
between	O
ALK	B-GP
and	O
STAT3	B-GP
was	O
observed	O
(	O
Fig	O
.	O
2B	O
,	O
lane	O
3	O
).	O

This	O
interaction	O
was	O
abrogated	O
by	O
addition	O
of	O
the	O
ALK	B-GP
inhibitor	O
crizotinib	O
(	O
Fig	O
.	O
2B	O
,	O
lane	O
4	O
).	O

Similarly	O
,	O
on	O
cotransfection	O
of	O
activated	O
ALKF1174S	O
with	O
FLAG	B-GP
-	O
tagged	O
STAT3	B-GP
,	O
an	O
interaction	O
was	O
observed	O
that	O
was	O
blocked	O
upon	O
addition	O
of	O
crizotinib	O
prior	O
to	O
immunoprecipitation	O
(	O
Fig	O
.	O
2B	O
,	O
compare	O
lanes	O
5	O
and	O
6	O
).	O

Similarly	O
,	O
we	O
were	O
able	O
to	O
observe	O
STAT3	B-GP
in	O
both	O
wild	O
-	O
type	O
and	O
gain	O
-	O
of	O
-	O
function	O
ALK	B-GP
immunoprecipitates	O
from	O
PC12	O
cells	O
transiently	O
expressing	O
ALK	B-GP
and	O
STAT3	B-GP
(	O
Fig	O
.	O
2C	O
).	O

In	O
agreement	O
with	O
our	O
previous	O
observations	O
,	O
the	O
STAT3	B-GP
–	O
ALK	B-GP
interaction	O
was	O
crizotinib	O
-	O
sensitive	O
(	O
Fig	O
.	O
2C	O
,	O
compare	O
lanes	O
3	O
and	O
5	O
with	O
lanes	O
4	O
and	O
6	O
).	O

Quantification	O
of	O
independent	O
blots	O
showed	O
clear	O
six	O
-	O
fold	O
to	O
10	O
-	O
fold	O
increased	O
binding	O
of	O
STAT3	B-GP
to	O
ALK	B-GP
upon	O
stimulation	O
or	O
when	O
a	O
gain	O
-	O
of	O
-	O
function	O
ALK	B-GP
variant	O
was	O
employed	O
(	O
Fig	O
.	O
S2	O
).	O

These	O
data	O
suggest	O
that	O
,	O
upon	O
activation	O
,	O
STAT3	B-GP
may	O
be	O
recruited	O
to	O
ALK	B-GP
signaling	O
complexes	O
.	O

However	O
,	O
it	O
is	O
important	O
to	O
note	O
that	O
our	O
attempts	O
to	O
verify	O
this	O
interaction	O
at	O
the	O
level	O
of	O
endogenous	O
proteins	O
in	O
neuroblastoma	B-DS
cell	O
lines	O
have	O
not	O
been	O
successful	O
.	O

STAT3	B-GP
is	O
important	O
for	O
MYCN	B-GP
expression	O
in	O
response	O
to	O
ALK	B-GP
activation	O

Given	O
recent	O
observations	O
that	O
ALK	B-GP
regulates	O
MYCN	B-GP
transcription	O
in	O
neuroblastoma	B-DS
cells	O
and	O
collaborates	O
with	O
MYCN	B-GP
in	O
neuroblastoma	B-DS
pathogenesis	O
34	O
–	O
37	O
,	O
we	O
decided	O
to	O
investigate	O
a	O
role	O
for	O
STAT3	B-GP
in	O
this	O
process	O
.	O

Initially	O
,	O
we	O
employed	O
small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
targeting	O
STAT3	B-GP
in	O
a	O
number	O
of	O
neuroblastoma	B-DS
cell	O
lines	O
,	O
including	O
CBL	O
-	O
GE	O
,	O
CBL	O
-	O
BAR	O
,	O
CBL	O
-	O
GA	O
and	O
Kelly	O
cells	O
.	O

These	O
neuroblastoma	B-DS
cell	O
lines	O
are	O
all	O
ALK	B-GP
gain	O
-	O
of	O
-	O
function	O
in	O
nature	O
,	O
containing	O
either	O
an	O
activated	O
ALK	B-GP
mutation	O
(	O
ALKR1275Q	O
,	O
CBL	O
-	O
GA	O
;	O
ALKF1174V	O
,	O
CLB	O
-	O
GE	O
;	O
ALKF1174L	O
,	O
Kelly	O
)	O
or	O
overexpressing	O
an	O
ALK	B-GP
receptor	I-GP
with	O
an	O
extracellular	O
domain	O
deletion	O
(	O
CLB	O
-	O
BARΔexon	O
4	O
–	O
12	O
),	O
and	O
express	O
different	O
levels	O
of	O
MYCN	B-GP
(	O
Fig	O
.	O
S3	O
)	O
38	O
,	O
39	O
.	O

Cell	O
lines	O
were	O
transfected	O
with	O
either	O
scrambled	O
siRNA	O
,	O
two	O
independent	O
siRNAs	O
targeting	O
STAT3	B-GP
,	O
or	O
a	O
mock	O
control	O
.	O

In	O
each	O
cell	O
line	O
tested	O
,	O
the	O
scrambled	O
siRNA	O
transfection	O
did	O
not	O
reduce	O
STAT3	B-GP
levels	O
,	O
which	O
were	O
comparable	O
to	O
those	O
in	O
cells	O
with	O
control	O
transfection	O
without	O
siRNA	O
.	O

However	O
,	O
upon	O
transfection	O
with	O
specific	O
STAT3	B-GP
siRNA	O
,	O
all	O
cell	O
lines	O
tested	O
showed	O
reduced	O
levels	O
of	O
STAT3	B-GP
as	O
compared	O
with	O
the	O
scrambled	O
transfection	O
controls	O
(	O
Fig	O
.	O
3A	O
–	O
D	O
,	O
top	O
panels	O
,	O
compare	O
lanes	O
3	O
and	O
4	O
with	O
lane	O
2	O
).	O

Furthermore	O
,	O
a	O
clear	O
reduction	O
in	O
MYCN	B-GP
levels	O
in	O
CLB	O
-	O
BAR	O
,	O
CLB	O
-	O
GA	O
and	O
Kelly	O
cells	O
was	O
observed	O
upon	O
treatment	O
with	O
siRNA	O
targeting	O
STAT3	B-GP
(	O
Fig	O
.	O
3A	O
–	O
D	O
,	O
middle	O
panels	O
,	O
compare	O
lanes	O
3	O
and	O
4	O
with	O
lane	O
2	O
).	O

Loss	O
of	O
STAT3	B-GP
results	O
in	O
reduced	O
MYCN	B-GP
levels	O
.	O

Two	O
independent	O
STAT3	B-GP
siRNAs	O
(#	O
1	O
or	O
#	O
2	O
)	O
were	O
employed	O
to	O
downregulate	O
STAT3	B-GP
levels	O
in	O
CLB	O
-	O
GE	O
(	O
A	O
),	O
CLB	O
-	O
BAR	O
(	O
B	O
),	O
Kelly	O
(	O
C	O
)	O
and	O
CLB	O
-	O
GA	O
(	O
D	O
)	O
neuroblastoma	B-DS
cell	O
lines	O
.	O

Cells	O
were	O
transfected	O
with	O
either	O
control	O
scrambled	O
siRNA	O
,	O
STAT3	B-GP
siRNA	O
#	O
1	O
or	O
STAT3	B-GP
siRNA	O
#	O
2	O
prior	O
to	O
cell	O
lysis	O
48	O
h	O
post	O
-	O
transfection	O
.	O

Whole	O
cell	O
lysates	O
were	O
subsequently	O
immunoblotted	O
for	O
STAT3	B-GP
,	O
MYCN	B-GP
,	O
and	O
pan	O
-	O
ERK	B-GP
(	O
as	O
loading	O
control	O
),	O
as	O
indicated	O
.	O

Lfm	O
,	O
lipofectamine	O
;	O
scC	O
,	O
scramble	O
control	O
.	O

To	O
further	O
validate	O
these	O
results	O
,	O
we	O
employed	O
a	O
number	O
of	O
STAT3	B-GP
inhibitors	O
,	O
including	O
FLLL32	O
and	O
STATTIC	O
,	O
which	O
have	O
previously	O
been	O
shown	O
to	O
inhibit	O
STAT3	B-GP
activation	O
41	O
,	O
42	O
.	O

We	O
investigated	O
ALK	B-GP
,	O
STAT3	B-GP
and	O
MYCN	B-GP
levels	O
in	O
CLB	O
-	O
GE	O
,	O
CLB	O
-	O
BAR	O
,	O
Kelly	O
and	O
CLB	O
-	O
GA	O
neuroblastoma	B-DS
cell	O
lines	O
upon	O
treatment	O
with	O
STAT3	B-GP
inhibitors	O
(	O
Fig	O
.	O
4A	O
–	O
D	O
).	O

Treatment	O
with	O
either	O
FLLL32	O
or	O
STATTIC	O
efficiently	O
abrogated	O
the	O
phosphorylation	O
of	O
STAT3	B-GP
without	O
affecting	O
general	O
STAT3	B-GP
levels	O
.	O

Importantly	O
,	O
whereas	O
these	O
inhibitors	O
blocked	O
STAT3	B-GP
activity	O
,	O
they	O
did	O
not	O
affect	O
the	O
phosphorylation	O
status	O
of	O
ERK	B-GP
or	O
ALK	B-GP
itself	O
(	O
Fig	O
.	O
4A	O
–	O
D	O
,	O
compare	O
lanes	O
3	O
and	O
4	O
with	O
lane	O
1	O
).	O

In	O
keeping	O
with	O
the	O
results	O
obtained	O
with	O
STAT3	B-GP
siRNA	O
treatment	O
,	O
both	O
inhibitors	O
reduced	O
MYCN	B-GP
levels	O
(	O
Fig	O
.	O
4A	O
–	O
D	O
,	O
compare	O
lanes	O
3	O
and	O
4	O
with	O
lane	O
1	O
),	O
suggesting	O
that	O
STAT3	B-GP
may	O
act	O
between	O
the	O
ALK	B-GP
receptor	I-GP
and	O
expression	O
of	O
MYCN	B-GP
.	O

The	O
ALK	B-GP
inhibitor	O
crizotinib	O
was	O
employed	O
as	O
a	O
control	O
,	O
leading	O
to	O
a	O
reduction	O
in	O
the	O
phosphorylation	O
of	O
STAT3	B-GP
and	O
ALK	B-GP
,	O
expression	O
of	O
MYCN	B-GP
and	O
phosphorylation	O
of	O
ERK	B-GP
(	O
Fig	O
.	O
4A	O
–	O
D	O
,	O
compare	O
lane	O
2	O
with	O
lanes	O
1	O
,	O
3	O
and	O
4	O
).	O

STAT3	B-GP
activity	O
is	O
required	O
for	O
regulation	O
of	O
MYCN	B-GP
expression	O
by	O
ALK	B-GP
.	O

Neuroblastoma	B-DS
cell	O
lines	O
CLB	O
-	O
GE	O
(	O
A	O
),	O
CLB	O
-	O
BAR	O
(	O
B	O
),	O
Kelly	O
(	O
C	O
)	O
and	O
CLB	O
-	O
GA	O
(	O
D	O
)	O
were	O
starved	O
and	O
treated	O
with	O
either	O
250	O
nm	O
crizotinib	O
(	O
24	O
h	O
),	O
5	O
μm	O
FLLL32	O
(	O
8	O
h	O
),	O
5	O
μm	O
STATTIC	O
(	O
8	O
h	O
),	O
or	O
control	O
,	O
as	O
indicated	O
.	O

After	O
cell	O
lysis	O
,	O
samples	O
were	O
immunoblotted	O
with	O
antibodies	O
against	O
p	O
-	O
ALKY1278	O
,	O
MYCN	B-GP
,	O
p	O
-	O
STAT3Y705	O
,	O
and	O
p	O
-	O
ERK	B-GP
.	O

Pan	O
-	O
ERK	B-GP
,	O
ALK	B-GP
and	O
STAT3	B-GP
antibodies	O
were	O
employed	O
as	O
loading	O
controls	O
.	O

Three	O
independent	O
experiments	O
with	O
similar	O
results	O
were	O
performed	O
,	O
and	O
representative	O
blots	O
are	O
shown	O
.	O

To	O
investigate	O
further	O
whether	O
STAT3	B-GP
is	O
involved	O
in	O
ALK	B-GP
-	O
activated	O
initiation	O
of	O
MYCN	B-GP
transcription	O
,	O
we	O
employed	O
an	O
MYCNP	O
–	O
luciferase	B-GP
assay	O
in	O
two	O
independent	O
neuroblastoma	B-DS
cell	O
lines	O
36	O
.	O

Cells	O
were	O
transfected	O
with	O
MYCNP	O
–	O
luciferase	B-GP
reporter	O
or	O
control	O
,	O
and	O
treated	O
with	O
either	O
STATTIC	O
or	O
FLLL32	O
.	O

Upon	O
treatment	O
with	O
STAT3	B-GP
inhibitors	O
,	O
both	O
cell	O
lines	O
showed	O
reduced	O
luciferase	B-GP
activity	O
as	O
compared	O
with	O
untreated	O
cells	O
(	O
Fig	O
.	O
5A	O
).	O

Additionally	O
,	O
we	O
employed	O
quantitative	O
RT	O
-	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
to	O
confirm	O
a	O
role	O
for	O
STAT3	B-GP
in	O
ALK	B-GP
regulation	O
of	O
MYCN	B-GP
transcription	O
.	O

As	O
controls	O
,	O
we	O
employed	O
primers	O
amplifying	O
part	O
of	O
the	O
coding	O
sequence	O
of	O
ribosomal	B-GP
protein	I-GP
29	I-GP
(	O
RPL29	B-GP
)	O
or	O
ribosomal	B-GP
protein	I-GP
19	I-GP
(	O
RPL19	B-GP
)	O
(	O
Fig	O
.	O
5B	O
,	O
data	O
not	O
shown	O
).	O

Neuroblastoma	B-DS
cell	O
lines	O
treated	O
with	O
STATTIC	O
or	O
FLLL32	O
for	O
24	O
h	O
showed	O
a	O
significant	O
reduction	O
in	O
MYCN	B-GP
mRNA	O
levels	O
in	O
comparison	O
with	O
untreated	O
cells	O
(	O
Fig	O
.	O
5B	O
).	O

Thus	O
,	O
pharmacological	O
inhibition	O
of	O
STAT3	B-GP
activity	O
in	O
neuroblastoma	B-DS
cell	O
lines	O
harboring	O
ALK	B-GP
gain	O
-	O
of	O
-	O
function	O
mutations	O
results	O
in	O
reduced	O
transcription	O
of	O
MYCN	B-GP
mRNA	O
.	O

Inhibition	O
of	O
STAT3	B-GP
reduces	O
MYCN	B-GP
transcription	O
.	O

(	O
A	O
)	O
Luciferase	B-GP
assay	O
of	O
neuroblastoma	B-DS
cell	O
lines	O
transfected	O
with	O
MYCNP	O
–	O
luciferase	B-GP
or	O
empty	O
pGL2	O
vector	O
as	O
a	O
control	O
(	O
ctrl	O
).	O

The	O
neuroblastoma	B-DS
cell	O
lines	O
CLB	O
-	O
GE	O
and	O
CLB	O
-	O
BAR	O
were	O
transfected	O
with	O
empty	O
pGL2	O
(	O
ctrl	O
)	O
or	O
MYCNP	O
–	O
luciferase	B-GP
.	O

Cells	O
were	O
then	O
serum	O
-	O
starved	O
,	O
and	O
STAT3	B-GP
was	O
inhibited	O
with	O
2	O
.	O
5	O
μm	O
FLLL32	O
or	O
STATTIC	O
for	O
12	O
h	O
.	O

White	O
bars	O
:	O
untreated	O
neuroblastoma	B-DS
cells	O
.	O

Gray	O
bars	O
:	O
cells	O
treated	O
with	O
FLLL32	O
.	O

Black	O
bars	O
:	O
cells	O
treated	O
with	O
STATTIC	O
.	O

Results	O
are	O
presented	O
as	O
relative	O
luciferase	B-GP
activity	O
,	O
where	O
untreated	O
samples	O
transfected	O
with	O
empty	O
pGL2	O
vector	O
were	O
set	O
to	O
1	O
.	O

(	O
B	O
)	O
qRT	O
-	O
PCR	O
of	O
MYCN	B-GP
mRNA	O
in	O
neuroblastoma	B-DS
cell	O
lines	O
.	O

The	O
neuroblastoma	B-DS
cell	O
lines	O
CLB	O
-	O
GE	O
and	O
CLB	O
-	O
BAR	O
were	O
starved	O
and	O
treated	O
with	O
2	O
.	O
5	O
μm	O
FLLL32	O
or	O
STATTIC	O
for	O
12	O
h	O
.	O

Primers	O
amplifying	O
part	O
of	O
the	O
coding	O
sequence	O
of	O
RPL19	B-GP
(	O
B	O
)	O
or	O
RPL29	B-GP
(	O
data	O
not	O
shown	O
)	O
were	O
used	O
to	O
control	O
for	O
differences	O
in	O
cDNA	O
input	O
.	O

Relative	O
expression	O
was	O
calculated	O
according	O
to	O
the	O
ΔΔCt	O
relative	O
quantification	O
method	O
.	O

Each	O
sample	O
within	O
an	O
experiment	O
was	O
analyzed	O
in	O
duplicate	O
,	O
and	O
the	O
experiment	O
was	O
carried	O
out	O
at	O
least	O
three	O
times	O
.	O

White	O
bars	O
:	O
untreated	O
cells	O
.	O

Gray	O
bars	O
:	O
cells	O
treated	O
with	O
FLLL32	O
.	O

Black	O
bars	O
:	O
cells	O
treated	O
with	O
STATTIC	O
.	O

STAT3	B-GP
activity	O
is	O
required	O
for	O
growth	O
and	O
viability	O
of	O
neuroblastoma	B-DS
cells	O

We	O
then	O
investigated	O
whether	O
STAT3	B-GP
is	O
not	O
only	O
important	O
for	O
initiation	O
of	O
MYCN	B-GP
transcription	O
but	O
also	O
might	O
influence	O
the	O
proliferation	O
of	O
our	O
neuroblastoma	B-DS
cell	O
lines	O
.	O

In	O
this	O
analysis	O
,	O
we	O
employed	O
CLB	O
-	O
GE	O
,	O
CLB	O
-	O
BAR	O
,	O
Kelly	O
and	O
CLB	O
-	O
GA	O
neuroblastoma	B-DS
cell	O
lines	O
,	O
measuring	O
their	O
growth	O
in	O
response	O
to	O
treatment	O
with	O
the	O
STAT3	B-GP
inhibitor	O
FLLL32	O
or	O
STAT3	B-GP
siRNA	O
.	O

In	O
all	O
cell	O
lines	O
examined	O
,	O
reduction	O
of	O
endogenous	O
STAT3	B-GP
expression	O
levels	O
by	O
siRNA	O
or	O
treatment	O
with	O
the	O
STAT3	B-GP
inhibitor	O
FLLL32	O
resulted	O
in	O
a	O
decrease	O
in	O
cell	O
growth	O
as	O
compared	O
with	O
untreated	O
cells	O
(	O
Fig	O
.	O
6B	O
,	O
D	O
–	O
G	O
)	O
in	O
a	O
similar	O
manner	O
as	O
crizotinib	O
decreased	O
cell	O
growth	O
(	O
Fig	O
.	O
6A	O
).	O

Furthermore	O
,	O
it	O
was	O
clear	O
that	O
treatment	O
of	O
neuroblastoma	B-DS
cell	O
lines	O
with	O
either	O
FLLL32	O
or	O
crizotinib	O
reduced	O
the	O
phosphorylation	O
status	O
of	O
STAT3	B-GP
to	O
a	O
similar	O
degree	O
,	O
without	O
increasing	O
cleavage	O
of	O
poly	B-GP
(	I-GP
ADP	I-GP
-	I-GP
ribose	I-GP
)	I-GP
polymerase	I-GP
(	O
PARP	B-GP
),	O
which	O
was	O
used	O
as	O
a	O
measure	O
of	O
apoptosis	O
(	O
Fig	O
.	O
6C	O
).	O

Loss	O
of	O
STAT3	B-GP
function	O
decreases	O
neuroblastoma	B-DS
cell	O
proliferation	O
.	O

(	O
A	O
,	O
B	O
)	O
Neuroblastoma	B-DS
cell	O
lines	O
CLB	O
-	O
GE	O
(▪),	O
CLB	O
-	O
BAR	O
(▴),	O
Kelly	O
(‐)	O
and	O
CLB	O
-	O
GA	O
(•)	O
were	O
treated	O
with	O
250	O
nm	O
crizotinib	O
(	O
A	O
)	O
and	O
1	O
.	O
5	O
μm	O
FLLL32	O
(	O
B	O
)	O
for	O
5	O
days	O
.	O

Proliferation	O
was	O
analyzed	O
with	O
the	O
resazurin	O
cell	O
proliferation	O
assay	O
.	O

Values	O
are	O
reported	O
as	O
fold	O
relative	O
fluorescence	O
from	O
FLLL32	O
-	O
treated	O
cells	O
versus	O
relative	O
fluorescence	O
from	O
untreated	O
cells	O
(♦).	O

Results	O
are	O
from	O
three	O
representative	O
experiments	O
,	O
with	O
each	O
experiment	O
performed	O
in	O
triplicate	O
.	O

(	O
C	O
)	O
Neuroblastoma	B-DS
cell	O
lines	O
CLB	O
-	O
BAR	O
,	O
CLB	O
-	O
GE	O
,	O
CLB	O
-	O
GA	O
and	O
Kelly	O
were	O
grown	O
on	O
six	O
-	O
well	O
plates	O
with	O
complete	O
growth	O
medium	O
,	O
starved	O
,	O
and	O
treated	O
with	O
250	O
nm	O
crizotinib	O
and	O
1	O
.	O
5	O
μm	O
FLLL32	O
for	O
6	O
h	O
.	O

Cell	O
lysates	O
were	O
immunoblotted	O
with	O
antibodies	O
against	O
p	O
-	O
STAT3	B-GP
and	O
PARP	B-GP
.	O

Tubulin	B-GP
was	O
used	O
as	O
a	O
loading	O
control	O
.	O

(	O
D	O
–	O
G	O
)	O
CLB	O
-	O
BAR	O
(	O
D	O
),	O
CLB	O
-	O
GA	O
(	O
E	O
)	O
CLB	O
-	O
GE	O
(	O
F	O
)	O
and	O
Kelly	O
(	O
G	O
)	O
cell	O
lines	O
were	O
transfected	O
with	O
scrambled	O
siRNA	O
(	O
SiC	O
)	O
(▪),	O
STAT3	B-GP
siRNA	O
#	O
1	O
(	O
Si1	O
)	O
(▴)	O
or	O
STAT3	B-GP
siRNA	O
#	O
2	O
(	O
Si2	O
)	O
(▴)	O
at	O
0	O
and	O
24	O
h	O
.	O

Cell	O
viability	O
was	O
assessed	O
at	O
0	O
,	O
3	O
,	O
4	O
and	O
5	O
days	O
post	O
-	O
transfection	O
,	O
with	O
the	O
resazurin	O
assay	O
.	O

Values	O
are	O
reported	O
as	O
fold	O
relative	O
fluorescence	O
from	O
siRNA	O
-	O
transfected	O
cells	O
versus	O
relative	O
fluorescence	O
from	O
control	O
mock	O
-	O
transfected	O
cells	O
.	O

Results	O
are	O
from	O
one	O
of	O
three	O
representative	O
experiments	O
,	O
with	O
each	O
experiment	O
performed	O
in	O
triplicate	O
.	O

Discussion	O

It	O
is	O
interesting	O
to	O
compare	O
the	O
results	O
of	O
this	O
study	O
with	O
earlier	O
phosphoproteomics	O
analysis	O
on	O
oncogenic	O
ALK	B-GP
fusion	O
proteins	O
,	O
such	O
as	O
EML4	B-GP
–	O
ALK	B-GP
and	O
NPM	B-GP
–	O
ALK	B-GP
29	O
,	O
30	O
.	O

In	O
terms	O
of	O
phosphorylation	O
of	O
ALK	B-GP
itself	O
,	O
these	O
studies	O
identified	O
overlapping	O
but	O
not	O
identical	O
sites	O
in	O
the	O
ALK	B-GP
intracellular	O
domain	O
.	O

Activation	O
of	O
full	O
-	O
length	O
ALK	B-GP
results	O
in	O
phosphorylation	O
of	O
Tyr1278	O
,	O
Tyr1282	O
,	O
and	O
Tyr1283	O
,	O
which	O
lie	O
in	O
the	O
Y	O
′	O
RAS	O
′	O
YY	O
autophosphorylation	O
motif	O
in	O
the	O
activation	O
loop	O
.	O

Although	O
our	O
data	O
do	O
not	O
allow	O
us	O
to	O
comment	O
on	O
the	O
order	O
of	O
phosphorylation	O
within	O
the	O
Y	O
′	O
RAS	O
′	O
YY	O
motif	O
,	O
they	O
are	O
in	O
agreement	O
with	O
previous	O
studies	O
elucidating	O
the	O
mechanism	O
of	O
phosphorylation	O
44	O
,	O
45	O
,	O
and	O
further	O
support	O
the	O
use	O
of	O
antibodies	O
against	O
pTyr1278	O
as	O
an	O
indicator	O
of	O
ALK	B-GP
activation	O
.	O

Another	O
site	O
commonly	O
used	O
to	O
denote	O
activation	O
of	O
the	O
ALK	B-GP
receptor	I-GP
is	O
Tyr1604	O
,	O
which	O
is	O
situated	O
at	O
the	O
C	O
-	O
terminal	O
tail	O
of	O
the	O
receptor	O
,	O
and	O
has	O
been	O
reported	O
to	O
be	O
important	O
for	O
transformation	O
activity	O
and	O
docking	O
of	O
phospholipase	B-GP
Cγ	I-GP
in	O
studies	O
on	O
NPM	B-GP
–	O
ALK	B-GP
47	O
.	O

Although	O
antibodies	O
against	O
pTyr1604	O
are	O
commonly	O
used	O
to	O
assay	O
ALK	B-GP
activity	O
,	O
the	O
importance	O
of	O
Tyr1604	O
in	O
the	O
interaction	O
of	O
phospholipase	B-GP
Cγ	I-GP
with	O
full	O
-	O
length	O
ALK	B-GP
has	O
not	O
been	O
confirmed	O
.	O

The	O
identification	O
in	O
this	O
study	O
reinforces	O
the	O
potential	O
importance	O
of	O
this	O
tyrosine	O
in	O
ALK	B-GP
activation	O
.	O

Of	O
the	O
phosphorylated	O
tyrosines	O
identified	O
outside	O
of	O
the	O
activation	O
loop	O
,	O
Tyr1507	O
of	O
ALK	B-GP
lies	O
within	O
a	O
consensus	O
Shc	B-GP
-	O
binding	O
site	O
(	O
NPTpY	O
),	O
and	O
has	O
been	O
shown	O
to	O
be	O
critical	O
for	O
interaction	O
of	O
full	O
-	O
length	O
ALK	B-GP
with	O
Shc	B-GP
23	O
.	O

These	O
results	O
are	O
consistent	O
with	O
earlier	O
work	O
on	O
NPM	B-GP
–	O
ALK	B-GP
48	O
.	O

The	O
remaining	O
tyrosines	O
that	O
are	O
phosphorylated	O
in	O
response	O
to	O
ALK	B-GP
activation	O
identified	O
in	O
this	O
study	O
,	O
namely	O
Tyr1078	O
,	O
Tyr1092	O
,	O
Tyr1096	O
,	O
Tyr1131	O
,	O
Tyr1584	O
,	O
and	O
Tyr1586	O
,	O
have	O
been	O
poorly	O
characterized	O
in	O
the	O
context	O
of	O
the	O
full	O
-	O
length	O
ALK	B-GP
RTK	B-GP
,	O
and	O
determination	O
of	O
their	O
significance	O
requires	O
further	O
analysis	O
.	O

However	O
,	O
work	O
on	O
the	O
oncogenic	O
ALK	B-GP
fusion	O
proteins	O
implicates	O
these	O
residues	O
in	O
binding	O
of	O
IRS	B-GP
-	I-GP
1	I-GP
(	O
Tyr1096	O
)	O
48	O
,	O
and	O
SNT	B-GP
(	O
FRS2	B-GP
)	O
(	O
Tyr1096	O
and	O
Tyr1507	O
)	O
49	O
.	O

As	O
well	O
as	O
identifying	O
tyrosine	O
phosphorylation	O
sites	O
in	O
ALK	B-GP
,	O
we	O
observed	O
phosphorylation	O
of	O
Ser1086	O
,	O
Ser1281	O
and	O
Thr1597	O
on	O
ALK	B-GP
.	O

Although	O
this	O
finding	O
is	O
intriguing	O
,	O
the	O
significance	O
of	O
these	O
phosphorylation	O
events	O
is	O
unclear	O
.	O

Although	O
the	O
phosphorylation	O
of	O
RTKs	B-GP
on	O
serine	O
and	O
threonine	O
is	O
well	O
recognized	O
,	O
its	O
role	O
is	O
much	O
less	O
understood	O
than	O
that	O
of	O
tyrosine	O
phosphorylation	O
.	O

However	O
,	O
serine	O
/	O
threonine	O
phosphorylation	O
is	O
known	O
to	O
have	O
important	O
regulatory	O
functions	O
for	O
,	O
for	O
example	O
,	O
fibroblast	B-GP
growth	I-GP
factor	I-GP
receptor	I-GP
,	O
epidermal	B-GP
growth	I-GP
factor	I-GP
receptor	I-GP
50	O
–	O
51	O
,	O
and	O
Kit	B-GP
52	O
,	O
to	O
name	O
but	O
a	O
few	O
.	O

Although	O
information	O
on	O
the	O
phosphorylation	O
of	O
ALK	B-GP
itself	O
in	O
response	O
to	O
activation	O
represented	O
an	O
important	O
part	O
of	O
the	O
information	O
obtained	O
with	O
this	O
phosphoproteomics	O
approach	O
,	O
the	O
identification	O
of	O
candidate	O
molecules	O
phosphorylated	O
in	O
response	O
to	O
ALK	B-GP
activation	O
was	O
the	O
primary	O
aim	O
of	O
this	O
investigation	O
.	O

The	O
list	O
of	O
phosphoproteins	B-GP
contains	O
both	O
known	O
and	O
novel	O
ALK	B-GP
signaling	O
components	O
,	O
some	O
of	O
which	O
have	O
been	O
characterized	O
,	O
but	O
the	O
majority	O
of	O
which	O
remain	O
to	O
be	O
investigated	O
for	O
their	O
relevance	O
in	O
both	O
physiological	O
and	O
pathological	O
ALK	B-GP
signaling	O
.	O

Of	O
those	O
known	O
candidates	O
,	O
several	O
examples	O
can	O
be	O
briefly	O
mentioned	O
.	O

One	O
molecule	O
identified	O
in	O
our	O
screen	O
was	O
FRS2	B-GP
,	O
which	O
was	O
phosphorylated	O
on	O
Tyr349	O
in	O
response	O
to	O
ALK	B-GP
activation	O
.	O

FRS2	B-GP
has	O
previously	O
been	O
reported	O
to	O
bind	O
full	O
-	O
length	O
ALK	B-GP
,	O
although	O
the	O
binding	O
site	O
is	O
unclear	O
23	O
.	O

Similarly	O
,	O
MAPK1	B-GP
–	O
which	O
was	O
phosphorylated	O
on	O
Thr183	O
in	O
this	O
study	O
–	O
has	O
been	O
shown	O
by	O
several	O
groups	O
to	O
be	O
phosphorylated	O
upon	O
stimulation	O
of	O
the	O
ALK	B-GP
receptor	I-GP
53	O
.	O

One	O
of	O
the	O
major	O
tyrosine	O
-	O
phosphorylated	O
proteins	O
identified	O
in	O
this	O
study	O
was	O
STAT3	B-GP
,	O
which	O
was	O
phosphorylated	O
on	O
Tyr705	O
in	O
response	O
to	O
ALK	B-GP
activation	O
.	O

STAT3	B-GP
has	O
been	O
reported	O
to	O
be	O
phosphorylated	O
downstream	O
of	O
several	O
of	O
the	O
oncogenic	O
ALK	B-GP
fusion	O
proteins	O
25	O
,	O
27	O
.	O

To	O
date	O
,	O
although	O
several	O
articles	O
have	O
reported	O
STAT3	B-GP
phosphorylation	O
downstream	O
of	O
full	O
-	O
length	O
ALK	B-GP
,	O
the	O
significance	O
of	O
this	O
is	O
unclear	O
8	O
–	O
56	O
.	O

One	O
study	O
of	O
NPM	B-GP
–	O
ALK	B-GP
has	O
suggested	O
that	O
oncogenic	O
ALK	B-GP
binds	O
and	O
activates	O
STAT3	B-GP
directly	O
via	O
the	O
first	O
tyrosine	O
(	O
Tyr1278	O
)	O
in	O
the	O
Y	O
′	O
RAS	O
′	O
YY	O
motif	O
of	O
ALK	B-GP
45	O
.	O

The	O
crystal	O
structures	O
of	O
ALK	B-GP
show	O
that	O
unphosphorylated	O
Tyr1278	O
interacts	O
with	O
Cys1097	O
in	O
the	O
N	O
-	O
lobe	O
of	O
the	O
kinase	B-GP
,	O
implying	O
that	O
phosphorylation	O
of	O
Tyr1278	O
should	O
make	O
a	O
binding	O
site	O
for	O
STAT3	B-GP
available	O
,	O
consistent	O
with	O
this	O
hypothesis	O
.	O

In	O
this	O
study	O
,	O
we	O
saw	O
clear	O
phosphorylation	O
of	O
STAT3	B-GP
on	O
Tyr705	O
,	O
which	O
is	O
particularly	O
robust	O
in	O
response	O
to	O
oncogenic	O
forms	O
of	O
the	O
full	O
-	O
length	O
ALK	B-GP
receptor	I-GP
,	O
such	O
as	O
ALKF1174S	O
,	O
ALKΔexon	O
2	O
–	O
3	O
,	O
and	O
ALKΔexon	O
4	O
–	O
1239	O
,	O
55	O
.	O

Although	O
it	O
was	O
not	O
investigated	O
in	O
this	O
study	O
,	O
it	O
would	O
be	O
of	O
interest	O
to	O
examine	O
the	O
importance	O
of	O
STAT3	B-GP
phosphorylation	O
in	O
neuroblastoma	B-DS
cells	O
harboring	O
a	O
wild	O
-	O
type	O
nonactive	O
ALK	B-GP
receptor	I-GP
.	O

This	O
hypothesis	O
is	O
supported	O
by	O
inhibition	O
of	O
the	O
NB1	O
neuroblastoma	B-DS
cells	O
lines	O
with	O
crizotinib	O
,	O
which	O
resulted	O
in	O
a	O
loss	O
of	O
pSTAT3Y705	O
,	O
although	O
the	O
significance	O
of	O
STAT3	B-GP
for	O
cell	O
growth	O
was	O
not	O
discussed	O
54	O
.	O

In	O
light	O
of	O
the	O
activation	O
of	O
STAT3	B-GP
by	O
ALK	B-GP
,	O
we	O
also	O
investigated	O
the	O
interaction	O
of	O
ALK	B-GP
with	O
STAT3	B-GP
.	O

Indeed	O
,	O
we	O
observed	O
an	O
interaction	O
of	O
STAT3	B-GP
with	O
full	O
-	O
length	O
ALK	B-GP
when	O
overexpressed	O
;	O
however	O
,	O
this	O
was	O
not	O
detectable	O
at	O
the	O
level	O
of	O
endogenous	O
proteins	O
,	O
suggesting	O
that	O
care	O
should	O
be	O
taken	O
when	O
interpreting	O
these	O
results	O
.	O

It	O
is	O
unclear	O
whether	O
this	O
is	O
because	O
of	O
limitations	O
of	O
the	O
antibodies	O
employed	O
here	O
,	O
or	O
a	O
masking	O
of	O
the	O
epitope	O
by	O
the	O
interaction	O
,	O
or	O
simply	O
a	O
low	O
level	O
of	O
endogenous	O
interaction	O
.	O

Although	O
the	O
precise	O
molecular	O
mechanisms	O
underlying	O
ALK	B-GP
activation	O
of	O
STAT3	B-GP
are	O
unknown	O
,	O
it	O
is	O
clear	O
from	O
these	O
studies	O
that	O
loss	O
of	O
STAT3	B-GP
activity	O
,	O
either	O
by	O
RNA	O
interference	O
-	O
mediated	O
knockdown	O
of	O
STAT3	B-GP
or	O
by	O
addition	O
of	O
STAT3	B-GP
inhibitors	O
41	O
,	O
42	O
,	O
reduces	O
the	O
growth	O
and	O
viability	O
of	O
four	O
neuroblastoma	B-DS
lines	O
.	O

One	O
key	O
component	O
examined	O
here	O
was	O
the	O
effect	O
of	O
STAT3	B-GP
activity	O
on	O
MYCN	B-GP
levels	O
.	O

Recent	O
work	O
has	O
highlighted	O
the	O
cooperative	O
roles	O
of	O
ALK	B-GP
and	O
MYCN	B-GP
in	O
neuroblastoma	B-DS
,	O
with	O
ALK	B-GP
impacting	O
on	O
both	O
the	O
level	O
of	O
MYCN	B-GP
transcription	O
and	O
the	O
stability	O
of	O
the	O
MYCN	B-GP
protein	O
itself	O
34	O
–	O
37	O
.	O

Given	O
these	O
reports	O
,	O
our	O
finding	O
here	O
that	O
STAT3	B-GP
is	O
important	O
for	O
changes	O
in	O
MYCN	B-GP
levels	O
in	O
response	O
to	O
ALK	B-GP
signaling	O
is	O
significant	O
.	O

Indeed	O
,	O
inhibition	O
of	O
STAT3	B-GP
by	O
addition	O
of	O
inhibitors	O
,	O
or	O
by	O
RNA	O
interference	O
,	O
reduced	O
MYCN	B-GP
levels	O
even	O
in	O
the	O
presence	O
of	O
activated	O
ALK	B-GP
.	O

In	O
conclusion	O
,	O
our	O
phosphoproteomic	O
analysis	O
identifies	O
a	O
number	O
of	O
phosphorylation	O
sites	O
targeted	O
by	O
activation	O
of	O
the	O
ALK	B-GP
RTK	B-GP
.	O

One	O
prominent	O
target	O
identified	O
in	O
this	O
analysis	O
was	O
STAT3	B-GP
,	O
which	O
we	O
show	O
here	O
is	O
important	O
for	O
the	O
regulation	O
of	O
MYCN	B-GP
downstream	O
of	O
activated	O
ALK	B-GP
.	O

From	O
our	O
investigations	O
,	O
it	O
is	O
also	O
clear	O
that	O
there	O
is	O
a	O
difference	O
between	O
the	O
ability	O
of	O
wild	O
-	O
type	O
ALK	B-GP
to	O
activate	O
STAT3	B-GP
and	O
that	O
of	O
oncogenically	O
activated	O
forms	O
of	O
ALK	B-GP
.	O

The	O
molecular	O
mechanisms	O
underlying	O
this	O
difference	O
are	O
not	O
known	O
,	O
and	O
further	O
work	O
is	O
required	O
to	O
understand	O
this	O
.	O

This	O
work	O
suggests	O
that	O
STAT3	B-GP
inhibition	O
may	O
be	O
a	O
viable	O
approach	O
in	O
the	O
regulation	O
of	O
MYCN	B-GP
activity	O
in	O
neuroblastoma	B-DS
cells	O
,	O
and	O
may	O
have	O
potential	O
therapeutic	O
value	O
in	O
the	O
future	O
.	O

Experimental	O
procedures	O

Phosphotyrosine	O
profiling	O

Tyrosine	O
phosphorylation	O
profiling	O
of	O
PC12	O
cells	O
expressing	O
human	B-OG
ALK	B-GP
with	O
and	O
without	O
activation	O
of	O
ALK	B-GP
was	O
undertaken	O
by	O
immunoaffinity	O
purification	O
with	O
P	O
-	O
Tyr	O
-	O
100	O
(	O
Cell	O
Signaling	O
Technology	O
,	O
Danvers	O
,	O
MA	O
,	O
USA	O
),	O
followed	O
by	O
LC	O
-	O
MS	O
/	O
MS	O
.	O

This	O
was	O
performed	O
as	O
previously	O
described	O
29	O
–	O
57	O
,	O
except	O
that	O
20	O
and	O
0	O
.	O
8	O
pmol	O
of	O
the	O
stable	O
isotope	O
-	O
labeled	O
phosphotyrosine	O
peptides	O
EH	O
[	O
13C3	O
,	O
15N1	O
-	O
A	O
]	O
LLApYTLGVK	O
and	O
HTDDEMTGpYV	O
[	O
13C3	O
,	O
15N1	O
-	O
A	O
]	O
TR	O
,	O
respectively	O
,	O
were	O
spiked	O
into	O
each	O
cell	O
lysate	O
prior	O
to	O
phosphopeptide	O
purification	O
.	O

Mass	O
spectra	O
of	O
two	O
technical	O
replicates	O
were	O
searched	O
against	O
a	O
rat	B-OG
protein	O
database	O
supplemented	O
with	O
the	O
sequence	O
for	O
human	B-OG
ALK	B-GP
(	O
extracted	O
from	O
UniProtKB	O
/	O
TrEMBL	O
ver	O
.	O
2013_01	O
;	O
41	O
749	O
reviewed	O
and	O
unreviewed	O
sequences	O
)	O
with	O
maxquant	O
version	O
1	O
.	O
3	O
.	O
0	O
.	O
5	O
.	O

Standard	O
settings	O
were	O
used	O
in	O
maxquant	O
(	O
false	O
discovery	O
rate	O
of	O
<	O
1	O
%	O
at	O
the	O
protein	O
,	O
peptide	O
and	O
modification	O
site	O
levels	O
),	O
except	O
that	O
the	O
‘	O
match	O
between	O
runs	O
’	O
function	O
was	O
enabled	O
.	O

A	O
list	O
with	O
high	O
-	O
confidence	O
phosphorylation	O
site	O
identifications	O
was	O
generated	O
by	O
filtering	O
the	O
‘	O
Phospho	O
(	O
STY	O
)	O
sites	O
’	O
output	O
table	O
for	O
Localization	O
probability	O
>	O
75	O
%	O
and	O
Score	O
difference	O
>	O
5	O
.	O

Intensity	O
values	O
for	O
phosphorylation	O
sites	O
were	O
normalized	O
between	O
samples	O
by	O
using	O
correction	O
factors	O
based	O
on	O
the	O
intensity	O
values	O
of	O
the	O
phosphotyrosine	O
sites	O
of	O
the	O
heavily	O
labeled	O
peptide	O
standards	O
.	O

Changes	O
in	O
intensity	O
ratios	O
between	O
cells	O
with	O
activated	O
ALK	B-GP
and	O
control	O
cells	O
of	O
≥	O
5	O
were	O
considered	O
to	O
be	O
significantly	O
altered	O
.	O

Network	O
analysis	O

Rat	B-OG
–	O
human	B-OG
orthologs	O
were	O
extracted	O
from	O
ensembl	O
.	O

The	O
protein	O
–	O
protein	O
interactions	O
among	O
proteins	O
of	O
interest	O
were	O
retrieved	O
from	O
the	O
Protein	O
Interaction	O
Network	O
Analysis	O
platform	O
58	O
,	O
and	O
substrate	O
–	O
kinase	B-GP
relationships	O
were	O
downloaded	O
from	O
the	O
PhosphoSitePlus	O
database	O
59	O
.	O
cytoscape	O
60	O
was	O
used	O
for	O
visualization	O
of	O
networks	O
.	O

Cell	O
culture	O

Stable	O
PC12	O
Tet	O
-	O
on	O
clones	O
expressing	O
human	B-OG
pTTP	O
-	O
ALK	B-GP
(	O
wild	O
type	O
)	O
have	O
been	O
described	O
previously	O
33	O
–	O
56	O
.	O

Stable	O
clones	O
were	O
selected	O
in	O
DMEM	O
containing	O
10	O
%	O
horse	B-OG
serum	O
(	O
MP	O
Biomedicals	O
,	O
France	O
),	O
5	O
%	O
tetracycline	O
-	O
screened	O
fetal	O
bovine	B-OG
serum	O
(	O
Thermo	O
Scientific	O
“	O
HyClone	O
”,	O
Belgium	O
),	O
penicillin	O
,	O
streptomycin	O
,	O
l	O
-	O
glutamine	O
,	O
100	O
mg	O
·	O
mL	O
−	O
1	O
G418	O
,	O
and	O
2	O
mg	O
·	O
mL	O
−	O
1	O
puromycin	O
,	O
at	O
37	O
°	O
C	O
and	O
5	O
%	O
CO2	O
.	O

The	O
neuroblastoma	B-DS
cell	O
lines	O
CLB	O
-	O
GA	O
(	O
1p	O
deletion	O
,	O
11q	O
deletion	O
,	O
17q	O
gain	O
,	O
ALKR1275Q	O
mutation	O
),	O
CLB	O
-	O
GE	O
(	O
MYCN	B-GP
/	O
ALK	B-GP
-	O
amplified	O
,	O
ALKF1174V	O
mutation	O
,	O
1p	O
deletion	O
,	O
17q	O
gain	O
),	O
CLB	O
-	O
BAR	O
(	O
amplified	O
MYCN	B-GP
/	O
ALKΔexon	O
4	O
–	O
12	O
,	O
1p	O
deletion	O
,	O
17q	O
gain	O
)	O
and	O
Kelly	O
(	O
MYCN	B-GP
-	O
amplified	O
,	O
ALKF1174L	O
mutation	O
)	O
were	O
maintained	O
in	O
RPMI	O
-	O
1640	O
medium	O
supplemented	O
with	O
10	O
%	O
fetal	O
bovine	B-OG
serum	O
(	O
Sigma	O
,	O
Stockholm	O
,	O
Sweden	O
),	O
100	O
U	O
·	O
mL	O
−	O
1	O
penicillin	O
,	O
and	O
100	O
μg	O
·	O
mL	O
−	O
1	O
streptomycin	O
,	O
at	O
37	O
°	O
C	O
in	O
humidified	O
air	O
with	O
5	O
%	O
CO2	O
38	O
–	O
40	O
.	O

Cell	O
proliferation	O

CLB	O
-	O
GA	O
(	O
0	O
.	O
035	O
×	O
106	O
per	O
well	O
),	O
CLB	O
-	O
GE	O
(	O
0	O
.	O
025	O
×	O
106	O
per	O
well	O
),	O
CLB	O
-	O
BAR	O
(	O
0	O
.	O
05	O
×	O
106	O
per	O
well	O
)	O
and	O
Kelly	O
(	O
0	O
.	O
035	O
×	O
106	O
per	O
well	O
)	O
cells	O
were	O
seeded	O
in	O
collagen	O
-	O
coated	O
48	O
-	O
well	O
plates	O
overnight	O
,	O
and	O
,	O
starting	O
on	O
the	O
following	O
day	O
,	O
treated	O
with	O
FLLL32	O
(	O
1	O
.	O
5	O
μm	O
)	O
for	O
0	O
–	O
5	O
days	O
.	O

Cell	O
viability	O
was	O
determined	O
at	O
0	O
–	O
5	O
days	O
after	O
drug	O
treatment	O
,	O
with	O
55	O
μm	O
resazurin	O
(	O
Sigma	O
,	O
Stockholm	O
,	O
Sweden	O
)	O
61	O
.	O

After	O
2	O
h	O
at	O
37	O
°	O
C	O
,	O
the	O
amount	O
of	O
metabolized	O
resazurin	O
was	O
analyzed	O
as	O
relative	O
fluorescence	O
with	O
an	O
Infinit200	O
plate	O
reader	O
(	O
TEKAN	O
,	O
Männedorf	O
,	O
Switzerland	O
).	O

Results	O
are	O
from	O
one	O
of	O
three	O
representative	O
experiments	O
,	O
with	O
each	O
experiment	O
being	O
performed	O
in	O
triplicate	O
.	O

Results	O
are	O
presented	O
as	O
fold	O
relative	O
fluorescence	O
from	O
FLLL32	O
-	O
treated	O
cells	O
versus	O
relative	O
fluorescence	O
from	O
control	O
untreated	O
cells	O
.	O

Cell	O
lysis	O
and	O
immunoblotting	O

Cells	O
were	O
harvested	O
and	O
lysed	O
as	O
described	O
previously	O
33	O
–	O
36	O
.	O

Samples	O
were	O
boiled	O
in	O
SDS	O
/	O
PAGE	O
sample	O
buffer	O
,	O
and	O
analyzed	O
on	O
SDS	O
/	O
PAGE	O
gel	O
.	O

The	O
antibodies	O
used	O
were	O
anti	O
-	O
STAT3	B-GP
(#	O
9132	O
),	O
anti	O
-	O
p	O
-	O
STAT3	B-GP
(	O
Tyr705	O
)	O
(#	O
9145	O
),	O
anti	O
-	O
p	O
-	O
ALK	B-GP
(	O
Tyr1278	O
)	O
(#	O
6941	O
),	O
anti	O
-	O
p	O
-	O
ERK	B-GP
(	O
phospho	O
-	O
p44	B-GP
/	O
42	O
)	O
(#	O
9101	O
),	O
anti	O
-	O
N	B-GP
-	I-GP
MYC	I-GP
(#	O
9405	O
)	O
(	O
all	O
Cell	O
Signaling	O
Technology	O
,	O
MA	O
,	O
USA	O
),	O
anti	O
-	O
FLAG	B-GP
(	O
clone	O
M2	O
,	O
#	O
F3165	O
;	O
Sigma	O
,	O
Stockholm	O
,	O
Sweden	O
),	O
anti	O
-	O
ERK	B-GP
(	O
610123	O
;	O
BD	O
Transduction	O
,	O
Stockholm	O
,	O
Sweden	O
),	O
and	O
anti	O
-	O
ALK	B-GP
(	O
mAb135	O
and	O
mAb31	O
)	O
10	O
.	O

STAT3	B-GP
siRNA	O
transfection	O

Cells	O
were	O
transfected	O
with	O
siRNA	O
duplexes	O
STAT3VHS40491	O
(	O
siRNA	O
#	O
1	O
:	O
sense	O
,	O
5	O
′-	O
GCAGUUUCUUCAGAGCAGGUAUCUU	O
-	O
3	O
′;	O
antisense	O
,	O
5	O
′-	O
AAGAUACCUGCUCUGAAGAAACUGC	O
-	O
3	O
′)	O
and	O
STAT3VHS40497	O
(	O
siRNA	O
#	O
2	O
:	O
sense	O
,	O
5	O
′-	O
CCUGCAAGAGUCGAAUGAAUGUUCUCUAU	O
-	O
3	O
′;	O
antisense	O
,	O
5	O
′-	O
AUAGAGAACAUUCGACUCUUGCAGG	O
-	O
3	O
′)	O
with	O
Lipofectamine	O
2000	O
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
CA	O
,	O
USA	O
).	O

After	O
6	O
h	O
,	O
the	O
medium	O
was	O
changed	O
to	O
complete	O
medium	O
without	O
antibiotic	O
,	O
and	O
allowed	O
to	O
grow	O
for	O
24	O
or	O
48	O
h	O
.	O

Cells	O
were	O
collected	O
and	O
processed	O
for	O
immunoblotting	O
as	O
described	O
above	O
to	O
determine	O
the	O
levels	O
of	O
STAT3	B-GP
,	O
MYCN	B-GP
and	O
pan	O
-	O
ERK	B-GP
for	O
a	O
loading	O
control	O
.	O

Immunoprecipitation	O

PC12	O
cells	O
were	O
transfected	O
with	O
pcDNA3	O
–	O
hALK	O
or	O
pcDNA3	O
–	O
hALKF1174S	O
(	O
0	O
.	O
6	O
μg	O
per	O
2	O
×	O
106	O
cells	O
)	O
together	O
with	O
STAT3	B-GP
–	O
FLAG	B-GP
(	O
0	O
.	O
6	O
μg	O
per	O
2	O
×	O
106	O
cells	O
)	O
or	O
pcDNA3	O
(	O
1	O
.	O
2	O
μg	O
per	O
2	O
×	O
106	O
cells	O
),	O
with	O
the	O
Amaxa	O
Biosystems	O
(	O
Cologne	O
,	O
Germany	O
)	O
electroporation	O
procedure	O
.	O

Cells	O
were	O
harvested	O
,	O
and	O
cell	O
lysates	O
were	O
pretreated	O
with	O
protein	O
G	B-GP
–	I-GP
Sepharose	I-GP
(	O
Sigma	O
),	O
before	O
being	O
incubated	O
with	O
the	O
anti	O
-	O
FLAG	B-GP
M2	O
-	O
coupled	O
protein	O
G	B-GP
–	I-GP
Sepharose	I-GP
beads	O
overnight	O
at	O
4	O
°	O
C	O
,	O
washed	O
five	O
times	O
with	O
NaCl	O
/	O
Tris	O
,	O
boiled	O
in	O
sample	O
loading	O
buffer	O
,	O
run	O
on	O
an	O
SDS	O
/	O
PAGE	O
gel	O
,	O
transferred	O
to	O
poly	O
(	O
vinylidene	O
difluoride	O
)	O
membranes	O
,	O
and	O
probed	O
with	O
antibodies	O
as	O
indicated	O
.	O

Luciferase	B-GP
assay	O

Cells	O
(	O
2	O
×	O
105	O
)	O
of	O
the	O
neuroblastoma	B-DS
cell	O
lines	O
CLB	O
-	O
GE	O
and	O
CLB	O
-	O
BAR	O
were	O
transfected	O
with	O
empty	O
pGL2	O
(	O
control	O
)	O
or	O
MYCNP	O
–	O
luciferase	B-GP
,	O
by	O
the	O
use	O
of	O
Lipofectamine	O
2000	O
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Cells	O
were	O
then	O
serum	O
-	O
starved	O
,	O
and	O
STAT3	B-GP
was	O
inhibited	O
by	O
employing	O
2	O
.	O
5	O
μm	O
FLLL32	O
(	O
generated	O
in	O
the	O
laboratory	O
of	O
P	O
.-	O
K	O
.	O

Li	O
)	O
or	O
STATTIC	O
(	O
Sigma	O
,	O
St	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
for	O
12	O
h	O
.	O

Each	O
sample	O
within	O
an	O
experiment	O
was	O
analyzed	O
in	O
triplicate	O
,	O
and	O
the	O
experiment	O
was	O
carried	O
out	O
three	O
times	O
.	O

Results	O
are	O
presented	O
as	O
relative	O
luciferase	B-GP
activity	O
,	O
where	O
untreated	O
samples	O
transfected	O
with	O
empty	O
pGL2	O
vector	O
were	O
set	O
to	O
1	O
.	O

qRT	O
-	O
PCR	O

The	O
neuroblastoma	B-DS
cell	O
lines	O
CLB	O
-	O
GE	O
and	O
CLB	O
-	O
BAR	O
were	O
starved	O
and	O
treated	O
with	O
2	O
.	O
5	O
μm	O
FLLL32	O
or	O
STATTIC	O
for	O
12	O
h	O
.	O

RNA	O
was	O
isolated	O
with	O
the	O
NucleoSpin	O
RNA	O
II	O
Kit	O
(	O
Macherey	O
-	O
Nagel	O
,	O
Duren	O
,	O
Germany	O
).	O

One	O
microgram	O
of	O
total	O
RNA	O
was	O
reverse	O
-	O
transcribed	O
with	O
the	O
iScript	O
cDNA	O
Synthesis	O
Kit	O
(	O
Bio	O
-	O
Rad	O
,	O
Sundbyberg	O
,	O
Sweden	O
).	O

For	O
the	O
PCR	O
amplification	O
in	O
an	O
iCycler	O
iQ5	O
(	O
Bio	O
-	O
Rad	O
),	O
25	O
ng	O
of	O
cDNA	O
was	O
used	O
in	O
a	O
total	O
reaction	O
mixture	O
of	O
20	O
μL	O
containing	O
10	O
μL	O
of	O
Quantimix	O
Easy	O
SYG	O
Kit	O
(	O
Biotools	O
,	O
Madrid	O
,	O
Spain	O
),	O
250	O
nm	O
forward	O
and	O
reverse	O
primers	O
,	O
and	O
0	O
.	O
08	O
μL	O
of	O
fluorescein	O
(	O
USB	O
;	O
Affimetrix	O
,	O
Santa	O
Clara	O
,	O
CA	O
,	O
USA	O
).	O

Primers	O
amplifying	O
part	O
of	O
the	O
coding	O
sequence	O
of	O
RPL29	B-GP
were	O
used	O
to	O
control	O
for	O
differences	O
in	O
cDNA	O
input	O
.	O

The	O
following	O
primers	O
were	O
used	O
:	O
human	B-OG
MYCN	B-GP
(	O
forward	O
,	O
5	O
′-	O
ACCACAAGGCCCTCAGTACC	O
-	O
3	O
′;	O
reverse	O
,	O
5	O
′-	O
TCTCCACAGTGACCACGTCGATTT	O
-	O
3	O
′);	O
human	B-OG
RPL19	B-GP
(	O
forward	O
,	O
5	O
′-	O
AACACATCCACAAGCTGAAGGCAG	O
-	O
3	O
′;	O
reverse	O
,	O
5	O
′-	O
TCTTCACGGCGCTTGCGT	O
-	O
3	O
′);	O
and	O
human	B-OG
RPL29	B-GP
(	O
forward	O
,	O
5	O
′-	O
ATGGCCAAGTCCAAGAACCACA	O
-	O
3	O
′;	O
reverse	O
,	O
5	O
′-	O
TTGGCATTGTTGGCCTGCAT	O
-	O
3	O
′).	O

Relative	O
expression	O
was	O
calculated	O
according	O
to	O
the	O
ΔΔCt	O
relative	O
quantification	O
method	O
.	O

Each	O
sample	O
within	O
an	O
experiment	O
was	O
analyzed	O
in	O
duplicate	O
,	O
and	O
the	O
experiment	O
was	O
carried	O
out	O
at	O
least	O
three	O
times	O
.	O

Results	O
are	O
presented	O
as	O
relative	O
MYCN	B-GP
mRNA	O
expression	O
where	O
untreated	O
samples	O
were	O
set	O
to	O
1	O
.	O

